In final 60-month results of a phase 3 trial (6-month placebo-controlled period, then extension with all on lumasiran) in 39 patients with primary hyperoxaluria type 1, lumasiran was associated with sustained 54% mean urinary oxalate reductions and stable eGFR.
RCTn = 39
Frishberg et al. Final Results of the ILLUMINATE-A Phase 3 Clinical Trial of Lumasiran for Primary Hyperoxaluria 1